Editor’s Pick

Stocks making the biggest moves after hours: Lyft, Cisco, Vroom & more

Cisco shares fell more than 6% in after-hours trading despite reporting fiscal fourth-quarter profit and revenues that topped analysts’ expectations. The results, though better than what analysts polled by Refinitiv had anticipated, marked the first annual sales decline in three years. Investors may have positioned to sell the Dow component after Cisco said that it sees first-quarter revenues down 9% to 11% and associated per-share earnings between 41 and 47 cents.

Singapore to remove most coronavirus restrictions from Friday

Singapore will allow small gatherings and the reopening of restaurants and shops from June 19, its health ministry said on Monday, in a major easing of the city-state’s coronavirus restrictions.
Social gatherings of up to five people will be permitted from Friday, when the majority of activities resume after more than two months of restrictions, dubbed “circuit breaker” measures. Social distancing requirements will remain in place.

The UK is in ‘pole position’ for market recovery despite gloomy economic outlook, UBS says

U.K. GDP saw its sharpest contraction since 1979 in the first quarter, and the balance-of-trade deficit widened to £21.1 billion ($26.4 billion).
U.K. stocks currently trade at a 19% discount to the MSCI World index, versus an average of 7% since 2002, UBS strategists pointed out in a research note Wednesday.
S&P Global has cut its forecast for U.K. GDP in 2020 to an 8.1% contraction, warning of a “perfect storm” if Britain suffers a second wave of coronavirus infections and fails to negotiate a post-Brexit free trade agreement.

Coronavirus vaccine is closer than the market thinks, Wharton’s Jeremy Siegel predicts

Wharton finance professor Jeremy Siegel expects a game changer.

He predicts a coronavirus vaccine is closer than the market thinks.

“We’ve had almost no setbacks in the schedule developing the vaccine, and I think that’s where upside surprises can occur,” Siegel told CNBC’s “Trading Nation” on Tuesday. “We may find ourselves with a workable vaccine for high risk individuals by the end of the fall, early winter.”